LLY.US will spend an additional $5.3 billion on top of the $3.7 billion previously announced
The Zhitong Finance App learned that LLY.US (LLY.US) will spend an additional 5.3 billion US dollars on top of the 3.7 billion US dollars previously announced to increase the production capacity of the active pharmaceutical ingredient production site in the Lebanon region of Indiana.
The pharmaceutical company said the investment will increase production of tirzepatide, the active ingredient in the type 2 diabetes drug Mounjaro and the weight loss drug Zepbound, in addition to increasing the production of pipeline drugs.
The total production investment of LEAP Innovation Park reached 9 billion US dollars, making it the largest production investment in the company's history. According to Eli Lilly, the new investment will add 200 full-time jobs for engineers, scientists, operators, and laboratory technicians. Once fully operational, the plant will have 900 full time employees.
According to information, Eli Lilly's production site in the region broke ground in 2023. The plant is expected to begin production at the end of 2026 and expand in 2028.